Table 1. Baseline characteristics.
| All patients N = 107 | Periventricular WML progression N = 31 | No periventricular WML progression N =76 | P value | Deep WML progression N = 42 | No deep WML progression N = 65 | P value | |
|---|---|---|---|---|---|---|---|
| Male | 62 (57.9%) | 18 (58.1%) | 48 (63.2%) | 0.62 | 22 (52.4%) | 44 (67.7%) | 0.11 |
| Age (years) | 63.5 (± 11.8) | 69.2 (± 8.5) | 61.1 (± 12.2) | < 0.01 | 68.0 (± 9.7) | 60.5 (± 12.2) | < 0.01 |
| Vitamin B12 (pmol/L) | 208.0 (± 82.2) | 182.6 (± 75.2) | 218.3 (± 83.1) | 0.04 | 206.4 (± 103.6) | 209.0 (± 65.5) | 0.87 |
| Vitamin B12 <150 pmol/L | 28 (26.2%) | 13 (41.9%) | 15 (19.7%) | 0.02 | 13 (31.0%) | 15 (23.1%) | 0.37 |
| Extensive periventricular WML at baseline (Fazekas 3) | 31 (29.0%) | 18 (58.1%) | 13 (17.1%) | < 0.01 | 19 (45.2%) | 12 (18.5%) | < 0.01 |
| Extensive deep WML at baseline (Fazekas 2 + 3) | 33 (30.8%) | 17 (54.8%) | 16 (21.1%) | < 0.01 | 25 (59.5%) | 8 (12.3%) | < 0.01 |
| Hypertension | 71 (66.4%) | 21 (67.7%) | 50 (65.8%) | 0.85 | 30 (71.4%) | 41 (63.1%) | 0.37 |
| Diabetes Mellitus | 16 (15.0%) | 5 (16.1%) | 11 (14.5%) | 0.78 | 8 (19.0%) | 8 (12.3%) | 0.34 |
| Hypercholestrolemia | 79 (73.8%) | 26 (83.9%) | 53 (69.7%) | 0.13 | 32 (76.2%) | 47 (72.3%) | 0.66 |
| Current smoking | 48 (44.9%) | 14 (44.2%) | 34 (44.7%) | 0.97 | 15 (35.7%) | 33 (50.8%) | 0.13 |
| 24-hour mean arterial pressure (mmHg) at follow-up* | 102.1 (± 9.7) | 104.2 (± 9.0) | 101.2 (± 9.8) | 0.15 | 101.1 (± 9.1) | 102.7 (±10.0) | 0.44 |
WML: white matter lesions; * 6 missing data